Stifel raised the firm’s price target on Alnylam (ALNY) to $345 from $300 and keeps a Buy rating on the shares following the recent FDA approval of vutrisiran in ATTR-cardiomyopathy. Vutrisiran’s differentiated label, along with confirmation that Alnylam would maintain premium pricing, are “tailwinds for what is a highly anticipated commercial launch,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam initiated with a Buy at Redburn Atlantic
- Alnylam presents new data from HELIOS-B Phase 3 trial
- Alnylam Pharma’s Growth Potential Boosted by FDA Approval of Qfitlia and Promising Clinical Results
- Alnylam announces FDA approval of Qfitlia for treatment of hemophilia A or B
- Biotech Alert: Searches spiking for these stocks today